TGFB1 and leukemia: Interestingly, blockade of these cytokines or their respective receptors has shown promising clinical outcomes in several types of cancers, including leukemia (anti-IL-7Rα [205]), lung (anti-IL-1β [206]) and skin (anti-TGF-β1 [207]) cancers.